Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43363-43374

  Gao, Shui Ping ^a,b   Sun, He Fen ^a,b   Jiang, Hong Lin ^a,b   Li, Liang Dong ^a,b   Hu, Xin ^a   Xu, Xiao En ^a,b   Jin, Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

COX5B; Cytokine; Mitochondrial dysfunction; Proliferation; Senescence

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR1 ANTAGONIST; COX5B; CYTOCHROME C OXIDASE; CYTOKINE; GLUCOSE; INTERLEUKIN 8; LACTIC ACID; UNCLASSIFIED DRUG; COX5B PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; FEMALE; GLUCOSE TRANSPORT; HUMAN; METABOLIC DISORDER; PROTEIN EXPRESSION; SENESCENCE; ANIMAL; BREAST TUMOR; CELL AGING; CELL MOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MITOCHONDRION; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ELECTRON TRANSPORT COMPLEX IV; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84952931536     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6222     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Eccles SA and Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007; 369:1742-1757.
3. McBride HM, Neuspiel M and Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006; 16:R551-560.
4. Ames BN, Shigenaga MK and Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993; 90:7915-7922.
5. Gogvadze V, Orrenius S and Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008; 18:165-173.
6. Schieber M and Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24:R453-462.
7. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12:931-947.
8. Heerdt BG, Houston MA and Augenlicht LH. The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res. 2005; 65:9861-9867.
9. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
10. Gatenby RA and Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4:891-899.
11. Ferreira LM. Cancer metabolism: the Warburg effect today. Exp Mol Pathol. 2010; 89:372-380.
12. Andreyev AY, Kushnareva YE and Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 2005; 70:200-214.
13. Calvo SE and Mootha VK. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet. 2010; 11:25-44.
14. Chan HL, Gharbi S, Gaffney PR, Cramer R, Waterfield MD and Timms JF. Proteomic analysis of redox-and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine-and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics. 2005; 5:2908-2926.
15. Chan HL, Sinclair J and Timms JF. Proteomic analysis of redox-dependent changes using cysteine-labeling 2D DIGE. Methods Mol Biol. 2012; 854:113-128.
16. Xu X, Qiao M, Zhang Y, Jiang Y, Wei P, Yao J, Gu B, Wang Y, Lu J, Wang Z, Tang Z, Sun Y, Wu W, et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics. 2010; 10:1374-1390.
17. Galati D, Srinivasan S, Raza H, Prabu SK, Hardy M, Chandran K, Lopez M, Kalyanaraman B and Avadhani NG. Role of nuclear-encoded subunit Vb in the assembly and stability of cytochrome c oxidase complex: implications in mitochondrial dysfunction and ROS production. Biochem J. 2009; 420:439-449.
18. Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, Tsosie KS and Hecht SM. Selective tumor cell targeting by the disaccharide moiety of bleomycin. J Am Chem Soc. 2013; 135:2883-2886.
19. Chen YW, Chou HC, Lyu PC, Yin HS, Huang FL, Chang WS, Fan CY, Tu IF, Lai TC, Lin ST, Lu YC, Wu CL, Huang SH, et al. Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers. Funct Integr Genomics. 2011; 11:225-239.
20. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA and Petricoin EF, 3rd. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003; 3:1801-1810.
21. Dang C, Gottschling M, Manning K, O'Currain E, Schneider S, Sterry W, Stockfleth E and Nindl I. Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol Rep. 2006; 16:513-519.
22. Passos JF, Saretzki G and von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Res. 2007; 35:7505-7513.
23. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR and Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009; 324:1076-1080.
24. Kaelin WG, Jr. and McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013; 153:56-69.
25. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E and Peeper DS. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013; 498:109-112.
26. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A and Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65:177-185.
27. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfurst B, Walenta S, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013; 501:421-425.
28. Quail DF and Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19:1423-1437.
29. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB and Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004; 10:7157-7162.
30. Zakrzewska I, Kozlowski L and Wojtukiewicz M. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor]. Pol Merkur Lekarski. 2002; 13:302-304.
31. Basu D, Reyes-Mugica M and Rebbaa A. Role of the beta catenin destruction complex in mediating chemotherapyinduced senescence-associated secretory phenotype. PLoS One. 2012; 7:e52188.
32. Yu YC, Yang PM, Chuah QY, Huang YH, Peng CW, Lee YJ and Chiu SJ. Radiation-induced senescence in securindeficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways. Sci Rep. 2013; 3:1675.
33. Miyake M, Lawton A, Goodison S, Urquidi V and Rosser CJ. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract. 2014; 210:74-78.
34. Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE, Brekken RA, Awasthi N, He YL and Zhang CH. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett. 2015; 359:335-343.
35. Zhao Y, Sun X, Nie X, Sun L, Tang TS, Chen D and Sun Q. COX5B regulates MAVS-mediated antiviral signaling through interaction with ATG5 and repressing ROS production. PLoS Pathog. 2012; 8:e1003086.